Amryt Announces the Appointment of Sheila Frame as President Americas

DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel...

A Catalyst Filled Quarter Lies Around The Corner

My wife and I spent Good Friday in the car, driving up to Massachusetts to visit my number one newsletter fan; my mother. It...

Amryt Submits a New Drug Application to the US Food and Drug Administration for...

TW's Take: if approved, Oleogel-S10 is likely to become Amryt's largest drug franchise in very short order. Expect to hear about the acceptance and...

Amryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS

TW's Take: very encouraging data as a label expansion into FCS would potentially double the addressable market for the drug. Amryt continues to increase...

Amryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)

TW's Take: further progress as they march towards hopeful approval in EB, which should make Oleogel-S10 their largest product in short order. DUBLIN, Ireland, and...

Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin)...

TW's Take: very positive step forward in broadening the indications for Myalept. Management of Amryt continues to execute well and the stock remains deeply...

Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for...

TW's Take: this further expands the market opportunity for Myalepta, allowing continued growth of this franchise. We remain excited about AMYT as the expected...

Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

TW's Take: Amryt's team has continually demonstrated positive progress in expanding their existing franchises.  DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM:...

Blood In The Water

Good Morning Vietnam! Okay, I'll confess to exaggerating a little; I neither live nor work in a war zone. It only just felt like...

Amryt (AMYT): A Rare Find in Today’s Market… Growth At A Reasonable Price!

Growing nicely and trading under 20 times 2020 EBITDA, Amryt Pharma (AMYT) has somehow managed to build a global franchise in rare diseases yet...
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.